PGHH Announces 62nd AGM, FY26 Revenue at ₹4,290 Cr, PAT ₹857 Cr
Procter & Gamble Hygiene and Health Care Limited reported FY26 revenue of ₹4,290 crore and Profit After Tax (PAT) of ₹857 crore, a 19% increase. The company announced its 62nd AGM and recommended a final dividend of ₹60 per share, totaling ₹255 for the year. Key product innovations include Whisper Nights and Vicks Cough Syrup.
The announcement includes solid financial performance and strategic updates, which are important for investors. However, it does not contain any transformative events like mergers, acquisitions, or significant market share shifts that would warrant a 'HIGH' impact.
The company reported strong financial results with increased revenue and profit, along with positive commentary on strategic investments and product innovations. The recommended dividend also contributes to a positive sentiment.
Procter & Gamble Hygiene and Health Care Limited (PGHH) has announced its 62nd Annual General Meeting (AGM) for the financial year ended March 31, 2026. The company has also reported its financial results for the same period, with revenue from operations standing at ₹4,290 crore, a slight increase from the previous year. Profit After Tax (PAT) saw a significant rise of 19% to ₹857 crore, driven by targeted productivity and efficiency interventions.
The company's Managing Director, Kumar Venkatasubramanian, highlighted deliberate investments in consumer-centric innovation, brand building, and go-to-market capabilities, which are expected to strengthen competitiveness and position the business for sustained growth. Key product developments include enhancements in the Whisper Nights portfolio for improved comfort and leakage protection, and the Vicks Cough Syrup, a new premium offering combining science and tradition for effective cough relief. The Vicks ZzzQuil Natura Sleep Gummies were also upgraded with higher melatonin dosage and ashwagandha.
PGHH is committed to its integrated growth strategy, focusing on a strong product portfolio, superiority, productivity, constructive disruption, and an empowered organization. The company's CSR program, P&G Shiksha, has positively impacted over 1 crore children. The financial year 2025-26 saw a change in the company's financial year from July 1 - June 30 to April 1 - March 31, making direct comparison with the previous nine-month period challenging. The Board has recommended a final dividend of ₹60 per equity share, making the aggregate dividend for FY26 ₹255 per equity share.
What to do with a filing like this
Procter & Gamble Hygiene and Health Care Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Hygiene and Health Care Limited. Read the original for the full detail.